BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 32645344)

  • 1. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination.
    Sternberg A; Naujokat C
    Life Sci; 2020 Sep; 257():118056. PubMed ID: 32645344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
    Papageorgiou AC; Mohsin I
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
    Choudhary S; Silakari O
    Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases.
    Rossi GA; Sacco O; Mancino E; Cristiani L; Midulla F
    Infection; 2020 Oct; 48(5):665-669. PubMed ID: 32737833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.
    Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V
    PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.
    Samrat SK; Tharappel AM; Li Z; Li H
    Virus Res; 2020 Oct; 288():198141. PubMed ID: 32846196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
    Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
    Robson B
    Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
    Nicolau LAD; Nolêto IRSG; Medeiros JVR
    Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
    Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI
    Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potently neutralizing and protective human antibodies against SARS-CoV-2.
    Zost SJ; Gilchuk P; Case JB; Binshtein E; Chen RE; Nkolola JP; Schäfer A; Reidy JX; Trivette A; Nargi RS; Sutton RE; Suryadevara N; Martinez DR; Williamson LE; Chen EC; Jones T; Day S; Myers L; Hassan AO; Kafai NM; Winkler ES; Fox JM; Shrihari S; Mueller BK; Meiler J; Chandrashekar A; Mercado NB; Steinhardt JJ; Ren K; Loo YM; Kallewaard NL; McCune BT; Keeler SP; Holtzman MJ; Barouch DH; Gralinski LE; Baric RS; Thackray LB; Diamond MS; Carnahan RH; Crowe JE
    Nature; 2020 Aug; 584(7821):443-449. PubMed ID: 32668443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
    Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
    Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
    Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.
    Liu Z; Xiao X; Wei X; Li J; Yang J; Tan H; Zhu J; Zhang Q; Wu J; Liu L
    J Med Virol; 2020 Jun; 92(6):595-601. PubMed ID: 32100877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of angiotensin-converting enzyme 2 and proteases in COVID-19 patients: A potential role of cellular FURIN in the pathogenesis of SARS-CoV-2.
    Drak Alsibai K
    Med Hypotheses; 2020 Oct; 143():109893. PubMed ID: 32512290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.